Are Wall Street Analysts Predicting IDEXX Laboratories Stock Will Climb or Sink?
What it means
- What to watch: Drugmakers live and die by pipelines — what is in late-stage trials matters more than this quarter's sales.
- How the stock is trading: $IDXX -3.65% in the latest session.
- Timing: It came out pre-market, so the next session was the first that could react.
Where the stock stands
$IDXX last traded at $554.98, -3.65% on the session. That puts it 28% shy of its 52-week high of $769.98 and 11% clear of its low of $500.61 — in the lower part of the range. Over the year it has ranged 54% from low to high: a wide band — moves of several percent in a week come with the territory. These are latest-session quotes, not live prices — the live tape is on the $IDXX page.
How much coverage it is getting
Nothing else on $IDXX in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$IDXX earnings in 3 days, Monthly options expiration in 21 days and FOMC decision in 40 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
For the receipts, the $IDXX page has the full chart, the filings and the valuation model these figures come from. Comparing how two or three outlets frame the same story is the fastest way to separate the facts from the angle. Wook AI, above, can pull live figures and run the numbers on request — how far $IDXX is from its high, or how this week's coverage compares.
How this analysis was made
Yahoo Finance published it, and Wook filed it under Healthcare & Pharma. The wording pulls both ways — “climb” against “sink” — and the two sides cancel out, which is why it reads neutral at medium severity. It was matched to $IDXX. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Yahoo Finance published this on August 26, 2026. $IDXX has moved +0.28% ($553.44 to $554.98). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.